STOCK TITAN

[8-K] ORTHOPEDIATRICS CORP Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

OrthoPediatrics Corp. furnished an 8-K announcing its earnings for the quarter ended September 30, 2025. The press release, including unaudited condensed consolidated financial statements and other financial data, is attached as Exhibit 99.1 and incorporated by reference.

The information under Item 2.02 is furnished and not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.

OrthoPediatrics Corp. ha presentato un 8-K che annuncia i propri utili per il trimestre terminato il 30 settembre 2025. Il comunicato stampa, comprese le rendicontazioni finanziarie condensate non auditate e altri dati finanziari, è allegato come Allegato 99.1 e incorporato per riferimento.

Le informazioni sotto la Voce 2.02 sono fornite e non considerate come “depositate” ai sensi della Sezione 18 dello Exchange Act o incorporate per riferimento salvo quanto espressamente previsto.

OrthoPediatrics Corp. presentó un 8-K anunciando sus ganancias del trimestre terminado al 30 de septiembre de 2025. El comunicado de prensa, incluyendo estados financieros condensados no auditados y otros datos financieros, se adjunta como el Anexo 99.1 e incorporado por referencia.

La información bajo el Punto 2.02 se divulga y no se considera “presentada” bajo la Sección 18 de la Securities Exchange Act ni incorporada por referencia, salvo lo expresamente establecido.

OrthoPediatrics Corp. 은 2025년 9월 30일 종료된 분기에 대한 실적을 발표하는 8-K를 제출했습니다. 보도자료에는 감사되지 않은 요약 연결재무제표 및 기타 재무 데이터가 포함되어 있으며, 이는 Exhibit 99.1로 첨부되어 참조로 통합됩니다.

Item 2.02에 해당하는 정보는 제공되며 Exchange Act의 제18조에 따라 '제출된' 것으로 간주되지 않으며 특별히 명시된 경우를 제외하고 참조에 의해 통합되지 않습니다.

OrthoPediatrics Corp. a remis un 8-K annonçant ses résultats pour le trimestre se terminant le 30 septembre 2025. Le communiqué de presse, y compris les états financiers condensés consolidés non audités et d'autres données financières, est joint en tant qu’Exhibit 99.1 et incorporé par référence.

Les informations figurant sous l’article 2.02 sont fournies et ne sont pas considérées comme « déposées » en vertu de la Section 18 du Securities Exchange Act ni incorporées par référence, sauf disposition expresse.

OrthoPediatrics Corp. hat eine 8-K vorgelegt, in der die Ergebnisse für das Quartal zum 30. September 2025 gemeldet werden. Die Pressemitteilung, einschließlich ungeprüfter kondensierter konsolidierter Finanzabschlüsse und weiterer Finanzdaten, ist als Exhibit 99.1 beigefügt und durch Verweis einbezogen.

Die Informationen unter Punkt 2.02 werden bereitgestellt und gelten nicht als „eingeführt“ gemäß § 18 des Exchange Act bzw. durch Bezugnahme aufgenommen, außer wie ausdrücklich festgelegt.

شركة OrthoPediatrics Corp. قد قدمت نموذج 8-K يعلن عن أرباحها للربع المنتهي في 30 سبتمبر 2025. البيان الصحفي، بما في ذلك البيانات المالية المجمعة المختصرة غير المدققة وغير ذلك من البيانات المالية، مرفق كمعروض 99.1 ومدمج بالمرجع.

المعلومات الواردة في البند 2.02 مقدمة وليست مُعتبرة “مسجلة” بموجب القسم 18 من قانون التبادل (Exchange Act) أو مُدرجة بالمرجع إلا كما هو مذكور صراحة.

Positive
  • None.
Negative
  • None.

OrthoPediatrics Corp. ha presentato un 8-K che annuncia i propri utili per il trimestre terminato il 30 settembre 2025. Il comunicato stampa, comprese le rendicontazioni finanziarie condensate non auditate e altri dati finanziari, è allegato come Allegato 99.1 e incorporato per riferimento.

Le informazioni sotto la Voce 2.02 sono fornite e non considerate come “depositate” ai sensi della Sezione 18 dello Exchange Act o incorporate per riferimento salvo quanto espressamente previsto.

OrthoPediatrics Corp. presentó un 8-K anunciando sus ganancias del trimestre terminado al 30 de septiembre de 2025. El comunicado de prensa, incluyendo estados financieros condensados no auditados y otros datos financieros, se adjunta como el Anexo 99.1 e incorporado por referencia.

La información bajo el Punto 2.02 se divulga y no se considera “presentada” bajo la Sección 18 de la Securities Exchange Act ni incorporada por referencia, salvo lo expresamente establecido.

OrthoPediatrics Corp. 은 2025년 9월 30일 종료된 분기에 대한 실적을 발표하는 8-K를 제출했습니다. 보도자료에는 감사되지 않은 요약 연결재무제표 및 기타 재무 데이터가 포함되어 있으며, 이는 Exhibit 99.1로 첨부되어 참조로 통합됩니다.

Item 2.02에 해당하는 정보는 제공되며 Exchange Act의 제18조에 따라 '제출된' 것으로 간주되지 않으며 특별히 명시된 경우를 제외하고 참조에 의해 통합되지 않습니다.

OrthoPediatrics Corp. a remis un 8-K annonçant ses résultats pour le trimestre se terminant le 30 septembre 2025. Le communiqué de presse, y compris les états financiers condensés consolidés non audités et d'autres données financières, est joint en tant qu’Exhibit 99.1 et incorporé par référence.

Les informations figurant sous l’article 2.02 sont fournies et ne sont pas considérées comme « déposées » en vertu de la Section 18 du Securities Exchange Act ni incorporées par référence, sauf disposition expresse.

OrthoPediatrics Corp. hat eine 8-K vorgelegt, in der die Ergebnisse für das Quartal zum 30. September 2025 gemeldet werden. Die Pressemitteilung, einschließlich ungeprüfter kondensierter konsolidierter Finanzabschlüsse und weiterer Finanzdaten, ist als Exhibit 99.1 beigefügt und durch Verweis einbezogen.

Die Informationen unter Punkt 2.02 werden bereitgestellt und gelten nicht als „eingeführt“ gemäß § 18 des Exchange Act bzw. durch Bezugnahme aufgenommen, außer wie ausdrücklich festgelegt.

شركة OrthoPediatrics Corp. قد قدمت نموذج 8-K يعلن عن أرباحها للربع المنتهي في 30 سبتمبر 2025. البيان الصحفي، بما في ذلك البيانات المالية المجمعة المختصرة غير المدققة وغير ذلك من البيانات المالية، مرفق كمعروض 99.1 ومدمج بالمرجع.

المعلومات الواردة في البند 2.02 مقدمة وليست مُعتبرة “مسجلة” بموجب القسم 18 من قانون التبادل (Exchange Act) أو مُدرجة بالمرجع إلا كما هو مذكور صراحة.

OrthoPediatrics Corp. 已提交一份8-K,宣布截至2025年9月30日的季度业绩。新闻稿,包括未经审计的简明合并财务报表以及其他财务数据,作为 Exhibit 99.1 附件并通过引用并入。

第2.02项下的信息是“提供”的,并不被视为根据证券交易法第18条“已 filed”的信息,也不通过引用并入,除非另有明确规定。

0001425450FALSE00014254502023-05-012023-05-01


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
______________________

Date of Report (Date of earliest event reported): October 28, 2025
OrthoPediatrics Corp.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
001-3824226-1761833
(Commission File Number)(I.R.S. Employer Identification Number)
2850 Frontier Drive
Warsaw, Indiana
46582
(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (574) 268-6379
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.00025 par value per shareKIDSNasdaq Global Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act (17 CFR 230.405) or Rule 12b-2 under the Exchange Act (17 CFR 240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨



Item 2.02. Results of Operations and Financial Condition.

On October 28, 2025, OrthoPediatrics Corp. issued a press release announcing its earnings for the quarter ended September 30, 2025 and making other disclosures. The press release (including the accompanying unaudited condensed consolidated financial statements as of and for the quarter ended September 30, 2025, and other financial data) is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02, including the information incorporated by reference herein from Exhibit 99.1, is furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
Exhibit No.Description
99.1
Press release dated October 28, 2025 issued by OrthoPediatrics Corp.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
* * * * * *



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OrthoPediatrics Corp.
Date:   October 28, 2025By:/s/ Daniel J. Gerritzen
Daniel J. Gerritzen,
General Counsel and Secretary


- 2 -
Orthopedia

NASDAQ:KIDS

KIDS Rankings

KIDS Latest News

KIDS Latest SEC Filings

KIDS Stock Data

412.77M
16.88M
32.71%
71.29%
4.85%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
WARSAW